Avaliação do trióxido arsênico e do ácido retinoico all-trans para o tratamento da leucemia promielocítica aguda pediátrica.
15 Nov, 2021 | 13:34hComunicado de imprensa: Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy – NIH News Releases
Comentário no Twitter
Clinical trial showed that pediatric patients with acute promyelocytic leukemia (APL) have very high cure rates with treatment regimen that uses targeted therapy and no cytotoxic chemotherapy for standard risk APL or limited anthracycline for high risk APL https://t.co/V3mahhIb6Y
— JAMA Oncology (@JAMAOnc) November 11, 2021